Conference Coverage

VIDEO: Is the FDA’s black box on estrogen too ‘alarming’?


 

References

NATIONAL HARBOR, MD. – Does the Food and Drug Administration’s black-box warning on estrogen contribute to noncompliance – or worse, to clinicians being unwilling to prescribe estrogen treatments – leaving many women to suffer untreated menopause symptoms?

The leadership of the North American Menopause Society thinks so, and the organization has started a campaign to get the FDA to reconsider how it labels estrogen.

“We would like the label for low-dose, vaginal estrogen to better reflect the true safety and risk profile,” said Dr. JoAnn Manson, chair of this year’s NAMS scientific committee.

In a video interview, Dr. Manson discusses how the current black-box labeling may impede effective treatment, and why revised, more-nuanced estrogen labeling could improve outcomes for many women.

wmcknight@frontlinemedcom.com

On Twitter @whitneymcknight

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Laparoscopic myomectomy with enclosed transvaginal tissue extraction
MDedge ObGyn
Vaginal bowel control device shown safe, effective in pivotal trial
MDedge ObGyn
Laparoscopic dual-port contained power morcellation: An offered solution
MDedge ObGyn
Estrogen does not cause breast cancer
MDedge ObGyn
2014 Update on sexual dysfunction
MDedge ObGyn
After 3-year stumble, new weight-loss drug wins FDA approval
MDedge ObGyn
Conjugated estrogen plus bazedoxifene—a new approach to estrogen therapy
MDedge ObGyn
Ideal patient selection for this new approach to HT
MDedge ObGyn
New mobile app assists clinicians in assessing menopausal patients
MDedge ObGyn
PODCAST: Alternatives to hormone therapy exist for women with moderate to severe menopause symptoms
MDedge ObGyn